13 results about "Primary immunization" patented technology

The invention provides bovine ephemeral fever virus positive serum as well as a preparation method and application thereof. The preparation method comprises the following steps: culturing bovine ephemeral fever virus by using MDBK suspension cells, inactivating by using beta-propiolactone, concentrating by using a 500kd hollow fiber column to obtain an antigen solution, and emulsifying the antigen solution and 61VG adjuvant according to a mass ratio of 1: 1.5 to prepare the vaccine; carrying out primary immunization and secondary immunization on the receptor, collecting blood of which the serum neutralizing antibody titer is greater than 1: 4096 14-21 days after the secondary immunization, and separating to obtain positive serum. The positive serum can be used for specific test, identification test and the like of the bovine ephemeral fever virus, can also be used for preparing related reagents, kits and standard substances, and provides efficient and normative technical support for prevention and control of bovine ephemeral fever.

The application discloses a novel group B meningococcal outer membrane protein bifunctional carrier, relates to the technical field of biopharmaceutical processes, and discloses a group B meningococcal outer membrane protein bifunctional carrier and application of the bifunctional carrier in a meningitis combined vaccine. The bifunctional carrier is human H factor binding protein fHbp, and comprises two kinds of recombinant proteins BA and BB, and the amino acid sequences of the two kinds of recombinin proteins are SEQ ID No. 62 and SEQ ID No. 63 respectively. The BA protein is coupled with group A capsule polysaccharide to form a group A combined vaccine, the BB protein is coupled with group C capsule polysaccharide to form a group C combined vaccine, and the two are mixed to form a group ABC triple vaccine. Each dose of the triple vaccine contains 40 μg of group A / C polysaccharide, 160 μg of BA / BB protein in total and 1.0 mg of aluminum adjuvant. The BA and BB proteins are expressed by E. coli, are broken by high-pressure homogenization, and are purified by anion exchange chromatography, and the purity is greater than or equal to 95%. The triple vaccine can simultaneously induce immune responses to groups A, B and C of meningitis, the serum bactericidal titer is greater than or equal to 1:32 after primary immunization, and the titer is maintained for more than 56 days after three immunizations.

The invention discloses a method for preparing a high-titer polyclonal antibody from a Zika virus strain, which comprises the following steps: selecting the Zika virus strain, culturing in cells, and purifying virus particles with high purity to prepare an immunogen; an optimized animal immunization strategy is adopted and comprises the steps of selecting a proper host animal, applying a potent immunologic adjuvant, namely a Freund's adjuvant, and designing a scientific immunization program, so that humoral immune response of the host is stimulated to the maximum extent; when the titer of the antibody reaches a peak value, collecting antiserum, synthesizing hybridoma cells through splenocytes, and obtaining the high-purity polyclonal antibody through a multi-step purification technology. According to the method, high-purity and non-chemically-inactivated whole virus particles which retain natural conformation are used as immunogens, a mode of primary immunization and multiple booster immunization is adopted, a Freund's adjuvant is combined, animals are continuously stimulated to generate high-titer antibodies, non-specific antibodies and impurities are effectively removed through multi-step purification, and the immunogen immunogen is obtained. The target antibody with high purity and high specificity is obtained.

An aspect provides a vaccine composition for preventing tuberculosis comprising chorismate mutase. The vaccine composition alone may induce immunity specific to Mycobacterium tuberculosis, and when provided together with an immune adjuvant, the vaccine composition may induce immunity specific to tuberculosis more effectively. Furthermore, when an existing vaccine for tuberculosis is used as a prime and the vaccine composition according to an aspect including chorismite mutase is provided as a booster, the immunity specific to tuberculosis may be induced significantly more effectively.

The invention is applicable to the technical field of biology, and provides a streptococcus suis type 2 multi-epitope inhalation type subunit vaccine and application thereof. According to the invention, 4 CTL epitopes, 7 HTL epitopes and 6 B cell epitopes are screened out aiming at conserved epitopes of SS2 virulence factors SSU05-1022 and SpaA, the epitopes are fused by AAY / GPGPG / EAAAK linkers, L7 / L12 ribosomal protein is introduced as an adjuvant, and the inhalation type subunit vaccine 1022-SpaA V3 is constructed; the vaccine can improve the levels of sIgA and serum IgG of respiratory mucosa and activate related immune cells by virtue of 60 micrograms of intranasal primary immunization-enhanced immunization, so that a mucosa and system dual immune mechanism is formed; the survival rate of mice after SS2 multi-strain challenge reaches up to 100%, and the bacterial load can be reduced; and the vaccine is safe and non-toxic, is inhaled, saves cost and is suitable for industrial large-scale production.

The invention discloses a construction method and application of a toxoplasma gondii RH delta cenl1 attenuated vaccine strain, and belongs to the technical field of vaccine preparation. A CENL1 gene is knocked out from an RH delta ku80 strain through CRISPR / Cas9 mediated gene editing, so that a toxoplasma gondii RH delta cenl1 attenuated vaccine strain is obtained. The attenuated vaccine strain is a toxoplasma gondii live vaccine candidate strain with an attenuated characteristic, shows significantly reduced toxicity in a mouse body, and can induce the body to generate strong immune response mainly including Th1 type. Immune protection evaluation results show that mice surviving after primary immunization of RH delta cenl1 do not show a complete protection effect after being infected again by the high-toxicity RH strain, but the survival time of the immunized mice can be remarkably prolonged, the disease progress can be slowed down, and certain immune protection potential is shown. The invention provides an important experimental basis for screening of toxoplasma gondii attenuated live vaccines and optimization of immune prevention and control strategies.

The invention relates to the technical field of biological medicine, and discloses an application of astragalus polysaccharide extracted by optimizing an alcohol precipitation process as an H3N2 influenza vaccine adjuvant, the application comprises the following steps: mixing the astragalus polysaccharide and an H3N2 influenza vaccine to prepare an immune preparation, extracting the astragalus polysaccharide by an ethanol precipitation method with the final concentration of 80%, the yield of the astragalus polysaccharide is 7.0-9.0% (based on the dry weight of raw materials), and the content of the astragalus polysaccharide in the H3N2 influenza vaccine adjuvant is 1-5%. In addition, the immune preparation can be used for remarkably improving the serum H3N2HI titer (Plt; 0.05) of the method. According to the application of the astragalus polysaccharide extracted by the optimized alcohol precipitation process as the H3N2 influenza vaccine adjuvant, the yield is 7.0-9.0% through the optimized alcohol precipitation process such as a precise extraction process and an ethanol precipitation method with the final concentration of 80%, and the prepared astragalus polysaccharide remarkably improves the serum H3N2HI titer (Plt; 0.05), the early-stage enhancement of the immune effect of the vaccine is assisted, the immune enhancement effect is synergistically exerted by scientifically matching the vaccine and combining 800 [mu] g of each animal with 15 [mu] g of H3N2 vaccine for each animal by determining the additive amount, and the effectiveness of matching of the adjuvant and the vaccine is guaranteed.

The application belongs to the technical field of disease animal model construction method, and particularly relates to a construction of an animal model of rheumatoid arthritis. The application uses SIRT3 knockout female mice, induces an arthritis model through mBSA antigen, and after primary immunization and secondary immunization, the rheumatoid arthritis phenotype appears one week after the secondary immunization. The mouse obtained in the application can appear knee joint injury, local joint inflammatory cell infiltration and obvious increase of inflammatory factors after one to two weeks of modeling. The rheumatoid arthritis mouse model obtained in the application has short modeling cycle, high and stable incidence rate, and clear pathogenesis, and is convenient for researchers to widely use.

The present invention provides compositions, vaccines and methods for inducing protective immunity against an immunogen in humans. The protective immune response is obtained by using a saRNA, in particular a VRP vector as prime and a MVA for boost. Specifically, the present invention relates to genetically engineered (recombinant) VRP and MVA vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of an infectious virus such as EBV.

The invention relates to the technical field of IgY antibodies, in particular to a preparation method and application of an anti-human papilloma virus IgY antibody, and the preparation method comprises the following steps: S1, preparing an immunogen; s2, carrying out stepped immunization; s3, collection and pretreatment of hyper-immune eggs: from 18-25 days after primary immunization, collecting eggs laid by the immunized hens, and after surface disinfection, taking yolk liquid for later use; s4, preliminarily extracting an antibody; s5, preliminarily concentrating and purifying the antibody; s6, fine purification of the antibody; s7, performing preparation treatment on the antibody; according to the present invention, the HPV L1 virus-like particle (VLP) immunogen strategy is adopted, the cross protection potential of the high immunogenicity of the L1 VLP is completely performed, the efficient adjuvant system is matched, the poultry is effectively induced to produce the high titer neutralizing antibody with wide cross reactivity, and the defects of limited single antigen targeting type and narrow protection range are overcome.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody for HPV16 type E7 protein detection and application of the monoclonal antibody. E7 protein serving as an antigen and a Freund's complete adjuvant are mixed, then a mouse is subjected to primary immunization, then the E7 protein and a Freund's incomplete adjuvant are mixed, then the mouse is subjected to enhanced immunization, and the HPV16 type E7 protein detection monoclonal antibody is obtained. The monoclonal antibody for detecting the HPV16 type E7 protein is prepared by taking mouse splenocytes and myeloma cells to be fused to prepare hybridoma cells, then performing clone detection on the hybridoma cells to screen the hybridoma cells aiming at the specificity of the HPV16 type E7 protein, and finally obtaining the monoclonal antibody for detecting the HPV16 type E7 protein. According to the present invention, the HPV16 type E7 antigen detection kit is developed by using the immunochromatography method, and the kit has advantages of high sensitivity, strong specificity, simple operation and fast detection speed, and can be used for rapid screening diagnosis and illness state monitoring of HPV16.

The invention belongs to the technical field of chicken disease prevention, and particularly relates to a quadruple inactivated vaccine for preventing chicken diseases, which is prepared by respectively proliferating four viruses, namely a newcastle disease virus LaSota strain, an infectious bronchitis virus M41 strain, an infectious bursal disease virus BJQ902 strain and a viral arthritis virus T98 strain, on an SPF chicken embryo and a chicken embryo fibroblast to obtain a virus solution, the preparation method comprises the following steps: carrying out 2-4 times concentration, inactivating by using a formaldehyde solution, proportioning according to a certain ratio, emulsifying, preparing an inactivated vaccine, carrying out safety and immune effect tests on the inactivated vaccine by using SPF (specific pathogen free) chickens, carrying out serology and challenge protection tests on the inactivated vaccine, carrying out physical property detection on the prepared inactivated vaccine, and continuously observing for 14 days, according to the present invention, the immune effect test results show that the Newcastle disease antibody level can achieve more than 6.0 log2 after the immunization for 28 d, and the antibody titer after the secondary immunization of the infectious bronchitis is 9 times of the first immunization of the infectious bronchitis;

The present disclosure provides a combined vaccine against human respiratory syncytial virus (RSV) infection and a method thereof for inducing immune response. The combined vaccine includes: a first composition including an immunologically effective dosage of a replication-deficient human adenovirus type 26 vector contains a nucleotide encoding an antigenic protein of RSV and a pharmaceutically acceptable vector; and a second composition including an immunologically effective dosage of a replication-deficient chimpanzee adenovirus type 63 vector contains a nucleotide encoding an antigenic protein of RSV and a pharmaceutically acceptable vector. The first composition is a primary immunization composition and the second composition is a booster immunization composition; or vice versa. In the present disclosure, the combined vaccine is used for inducing a protective immunity against RSV infection, and a method is provided for generating the protective immunity against RSV infection.